Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/250681
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Gram-Positive Pneumonia: Possibilities Offered by Phage Therapy |
Autor: | Fernández Llamas, Lucía CSIC ORCID; Cima-Cabal, María Dolores; Duarte, Ana Catarina; Rodríguez González, Ana CSIC ORCID; García-Suárez, María del Mar; García Suárez, María Pilar CSIC ORCID | Palabras clave: | Pneumonia Antibiotic resistance Streptococcus pneumoniae Staphylococcus aureus New therapies Phage therapy Endolysins |
Fecha de publicación: | 18-ago-2021 | Editor: | Molecular Diversity Preservation International | Citación: | Antibiotics 10(8): 1000 (2021) | Resumen: | Pneumonia is an acute pulmonary infection whose high hospitalization and mortality rates can, on occasion, bring healthcare systems to the brink of collapse. Both viral and bacterial pneumonia are uncovering many gaps in our understanding of host–pathogen interactions, and are testing the effectiveness of the currently available antimicrobial strategies. In the case of bacterial pneumonia, the main challenge is antibiotic resistance, which is only expected to increase during the current pandemic due to the widespread use of antibiotics to prevent secondary infections in COVID-19 patients. As a result, alternative therapeutics will be necessary to keep this disease under control. This review evaluates the advantages of phage therapy to treat lung bacterial infections, in particular those caused by the Gram-positive bacteria Streptococcus pneumoniae and Staphylococcus aureus, while also highlighting the regulatory impediments that hamper its clinical use and the difficulties associated with phage research | Versión del editor: | https://doi.org/10.3390/antibiotics10081000 | URI: | http://hdl.handle.net/10261/250681 | DOI: | 10.3390/antibiotics10081000 | E-ISSN: | 2079-6382 |
Aparece en las colecciones: | (PTI Salud Global) Colección Especial COVID-19 (IPLA) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
antibiotics-10-01000-v2.pdf | 1,23 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
4
checked on 12-abr-2024
WEB OF SCIENCETM
Citations
4
checked on 27-feb-2024
Page view(s)
116
checked on 17-abr-2024
Download(s)
181
checked on 17-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons